Clinical Trials Logo

Thrombopenia clinical trials

View clinical trials related to Thrombopenia.

Filter by:
  • None
  • Page 1

NCT ID: NCT06455553 Not yet recruiting - Clinical trials for Hematologic Malignancies

Interpretability of the Quantra® Viscoelastic Test in Patients With Haematological Malignancies With Profound Thrombocytopenia Below 50x10 G/L.

VISCOTHEM-1
Start date: June 17, 2024
Phase: N/A
Study type: Interventional

The goal of this single-center, non-controlled, non-randomized exploratory clinical trial is to evaluate the interpretability of viscoelastic tests (Quantra® and ROTEM® type) in relation to platelet levels measured in standard biology in patients with haematological malignancies, hospitalized in day hospitals or full hematology wards, presenting thrombocytopenia strictly below 50 G/L. Participants will undergo an additional blood sample to standard care. The total volume of blood drawn will be 12.1 mL. The following analyses will be performed: Quantra®, Rotem®, blood count, platelets, immature platelet count, plasma prothrombin time, activated partial thromboplastin time, International Normalized Ratio, fibrinogen.

NCT ID: NCT05040776 Withdrawn - Covid19 Clinical Trials

COVID-19 ThromboprophylaXIs Study of Novel FXIa Inhibitor Frunexian (EP-7041) in ICU Patients

Start date: October 2023
Phase: Phase 2
Study type: Interventional

This is a multicenter, open-label, single cohort study of patients with confirmed COVID-19 syndrome who based on clinical judgment require care in an intensive care unit, regardless of whether or not mechanical ventilation is in use or is anticipated. Patients should be enrolled on the first day of the ICU stay; withdrawal of prior thromboprophylaxis, if any, will follow specific protocol guidance. Enrolled patients will thereafter be administered intravenous frunexian (EP-7041) until disposition from the hospital (including post-ICU non-critical care management)

NCT ID: NCT04070599 Completed - Clinical trials for Immune Thrombocytopenic Purpura

Initial Hemato-immunological Profile on the Evolution of Immunological Thrombopenic Purpura.

IMMUNOTI
Start date: April 12, 2011
Phase: Phase 3
Study type: Interventional

This study aims to determine the hemato-immunological parameters predictive of the evolution of a Immune thrombocytopenic purpura (ITP) towards chronicity, and to identify possible differences between the child and the adult.

NCT ID: NCT03823079 Not yet recruiting - Clinical trials for Recurrent Colorectal Carcinoma

Comparison of Interleukin-11 and rhTPO for Recurrent Colorectal Cancer Patients With Thrombocytopenia

Start date: February 1, 2019
Phase: Phase 2
Study type: Interventional

This randomized controlled clinical phase II study was designed to compare the effect of rhTPO with rhIL-11 in improving thrombocytopenia in patients with recurrent colorectal cancer who underwent radiotherapy and with thrombocytopenia.

NCT ID: NCT02906878 Recruiting - Thrombopenia Clinical Trials

Platelet Kinetics After Platelet Transfusion for the Placement of a Central Venous Catheter

PLATCAT
Start date: June 2016
Phase: N/A
Study type: Observational

PLATCAT study's purpose is to evaluate platelet kinetics after platelet transfusion

NCT ID: NCT01013181 Completed - Thrombopenia Clinical Trials

Safety and Efficacy of Romiplostim in Immune Thrombocytopenia (ITP) in the " Real-life " : Result of the French Experience in 72 Adults

ATU-r
Start date: January 2008
Phase: N/A
Study type: Observational

The purpose of this study is to review the charts of the first 100 patients included in the french compassionate program including patients with Immune Thrombopenia receiving romiplostim.

NCT ID: NCT00336687 Completed - Thrombopenia Clinical Trials

Study of Incidence, of Mechanisms and Prognosis of the Thrombopenia From Patients of Reanimation.

Start date: July 2005
Phase: N/A
Study type: Observational

About 40 % of the patients in reanimation are thrombopenics and the causes are not well known (reduction in platelet's production, increase in their destruction...). This protocol studies the epidemiology of thrombopenia for these patients and the impacts of cost and mortality in order to bring patients best medical cares.